On Tuesday, Dyne Therapeutics Inc. (NASDAQ:DYN) announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 ...
Monday, Dyne Therapeutics Inc (NASDAQ:DYN) released clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its ongoing Phase 1/2 ...
Dyne Therapeutics’ experimental treatment for Duchenne muscular dystrophy (DMD) showed promise in new data from a small Phase 1/2 trial dubbed DELIVER, the pharma announced this week. The drug, ...
Shares of Dyne Therapeutics, Inc. DYN, a clinical-stage muscle disease company, tumbled 30.7% on two key announcements. The company announced that some of its senior executives have stepped down from ...
- Initiating Registrational Cohorts with Update on Path to Registration by Year-End 2024 -- Virtual Investor Event Today at 8:00 a.m. ET- “We believe these data reinforce the opportunity to transform ...
Dyne Therapeutics Inc. shares DYN jumped 40% premarket on Wednesday after the company released new data from trials of two investigational treatments for genetic muscle disorders. The experimental ...
- Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne’s first planned commercial launch in early 2027 - - Registrational Expansion Cohort of DELIVER ...
Dyne Therapeutics is developing treatments for genetically driven muscle diseases, focusing on Myotonic Dystrophy Type 1 (DM1) and Duchenne Muscular Dystrophy (DMD). Their lead candidate, DYNE-101, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results